News
-
-
-
PRESS RELEASE
MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
MIRA Pharmaceuticals to acquire SKNY Pharmaceuticals, enhancing MIRA pipeline with oral drug SKNY-1 for weight loss and nicotine cravings reversal. Shareholders approve merger with $30 million valuation -
-
-
PRESS RELEASE
Progress in clinical development for Alzheimer´s and other indications: Galimedix Therapeutics successfully completes Phase 1 study with oral small molecule, GAL-101, an amyloid beta aggregation modul
Galimedix successfully completes Phase 1 study with GAL-101, a small molecule targeting amyloid beta in Alzheimer's disease. Phase 2 trial planned -
-
-
-
